menu
    • menu
    [{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Adocia"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"THDB0206","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"THDB0206","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Tonghua Dongbao Pharma \/ Tonghua Dongbao Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Tonghua Dongbao Pharma

    Menu

    Tonghua Dongbao Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Recipient : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia, Tonghua Dongbao Report Positive Ph 3 Results for Ultra-Rapid Insulin

                            Details : Insulin Lispro, a peptide targeting the insulin receptor, shows promise in treating Type 1 Diabetes.

                            Product Name : BioChaperone Lispro

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            October 15, 2025

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Recipient : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

                            Details : THDBH120 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 25, 2025

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            THDBH120 Safety, PK, and Efficacy In Chinese T2DM Patients

                            Details : THDBH120 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 13, 2025

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chi...

                            Details : THDBH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 30, 2025

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pha...

                            Details : THDBH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 20, 2024

                            Lead Product(s) : THDBH120

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Degludec

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type ...

                            Details : Insulin Degludec is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : Degludec

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Degludec

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Sub...

                            Details : Insulin Degludec is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            June 10, 2024

                            Lead Product(s) : Degludec

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THDB0206

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subject...

                            Details : THDB0206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 01, 2023

                            Lead Product(s) : THDB0206

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THDB0206

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

                            Details : THDB0206 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 28, 2023

                            Lead Product(s) : THDB0206

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tonghua Dongbao Pharma

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and HumalogÂÂ...

                            Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 13, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth